| 153.58 1.45 (0.95%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 188.66 | 1-year : | 220.36 |
| Resists | First : | 161.52 | Second : | 188.66 |
| Pivot price | 153.43  |
|||
| Supports | First : | 139.22 | Second : | 125.43 |
| MAs | MA(5) : | 153.42 |
MA(20) : | 150.68 |
| MA(100) : | 126.44 |
MA(250) : | 109.93 |
|
| MACD | MACD : | 5.4 |
Signal : | 6.2 |
| %K %D | K(14,3) : | 58.6 |
D(3) : | 64.4 |
| RSI | RSI(14): 62.2 |
|||
| 52-week | High : | 161.52 | Low : | 73.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GKOS ] has closed below upper band by 48.2%. Bollinger Bands are 69.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 155.96 - 156.99 | 156.99 - 157.92 |
| Low: | 148.45 - 149.77 | 149.77 - 150.95 |
| Close: | 151.55 - 153.62 | 153.62 - 155.49 |
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Fri, 24 Jul 2026
MSN Money - MSN
Thu, 23 Jul 2026
GKOS|Glaukos Corp|Price:153.402|Chg%:+1.272 - TradingKey
Tue, 21 Jul 2026
Glaukos Corp (NYSE: GKOS) CFO trades 10,000 shares under Rule 10b5-1 plan - Stock Titan
Mon, 20 Jul 2026
Glaukos (GKOS) Q1 2026 earnings summary - Quartr
Sat, 18 Jul 2026
How Glaukos Corporation (GKOS) Affects Rotational Strategy Timing - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 59 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 102.5 (%) |
| Shares Short | 4,450 (K) |
| Shares Short P.Month | 3,120 (K) |
| EPS | -3.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.5 |
| Profit Margin | -34.4 % |
| Operating Margin | -13.2 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -26.4 % |
| Qtrly Rev. Growth | 41.2 % |
| Gross Profit (p.s.) | 7.33 |
| Sales Per Share | 9.38 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -46.54 |
| PEG Ratio | 0 |
| Price to Book value | 13.35 |
| Price to Sales | 16.35 |
| Price to Cash Flow | -1026.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|